Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 182 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Motility Disorder Clear all
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

NCT01348061
View directory record Official record
Conditions
Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration

NCT00703677
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Lithium
Drug
Lead sponsor
Westat
Other
Eligibility
40 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Jul 21, 2026, 10:10 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Vision In Preschoolers Study (VIP Study)

NCT00038753
View directory record Official record
Conditions
Amblyopia, Strabismus, Refractive Error
Interventions
Vision Screening
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
36 Months to 59 Months
Healthy volunteers
Accepts healthy volunteers
U.S. locations
5
States / cities
Berkeley, California • Boston, Massachusetts • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2009 · Synced Jul 21, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
View directory record Official record
Conditions
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
Interventions
Amifampridine Phosphate
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

NCT02391961
View directory record Official record
Conditions
Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 2Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
Davunetide, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
41 Years to 85 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Randomized Trial of Treatments for Convergence Insufficiency

NCT00347945
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Pencil Push-ups, Office-based Vision Therapy, Placebo Office-based Vision Therapy
Procedure
Lead sponsor
Pennsylvania College of Optometry
Industry
Eligibility
9 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
7
States / cities
Fullerton, California • New York, New York • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2006 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
View directory record Official record
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Terminated Not applicable Interventional

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

NCT05307770
View directory record Official record
Conditions
Rapid Eye Movement Sleep Behavior Disorder, Parkinson Disease
Interventions
Immediate Release Melatonin, Extended Release Melatonin
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism

NCT01358474
View directory record Official record
Conditions
Parkinson Disease, Gaucher Disease, Idiopathic Rapid Eye Movement Sleep Disorder
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging

NCT03919708
View directory record Official record
Conditions
Amblyopia, Strabismus
Interventions
Retinal Birefringence Imager
Device
Lead sponsor
Rebiscan, Inc.
Industry
Eligibility
2 Years to 8 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

NCT05162768
View directory record Official record
Conditions
Mitochondrial Myopathies, Mitochondrial Pathology, Mitochondrial DNA Mutation, Mitochondrial Diseases, Mitochondrial DNA Deletion, Mitochondrial DNA Depletion, Mitochondrial Metabolism Defect, Mitochondrial Complex I Deficiency
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 10:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies

NCT03059420
View directory record Official record
Conditions
Congenital Fibrosis of Extraocular Muscles, Duane Retraction Syndrome, Duane Radial Ray Syndrome, Mobius Syndrome, Brown Syndrome, Marcus Gunn Syndrome, Strabismus Congenital, Horizontal Gaze Palsy, Horizontal Gaze Palsy With Progressive Scoliosis, Facial Palsy, Facial Paresis, Hereditary, Congenital, Third Nerve Palsy, Fourth Nerve Palsy, Sixth Nerve Palsy, Synkinesis, Ocular Motility Disorders, Levator-Medial Rectus Synkinesis, Athabaskan Brainstem Dysgenesis, Tongue Paralysis, Ninth Nerve Disorder, Fifth Nerve Palsy, Seventh Nerve Palsy, Eleventh Nerve Disorder, Twelfth Nerve Disorder, Vagus Nerve Paralysis, Moebius Sequence
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Training Attention and Eye Movement in ASD

NCT02403817
View directory record Official record
Conditions
Autistic Disorder, Autism Spectrum Disorder
Interventions
Cognitive Training, Eye Motor Training, Hand Motor Training
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
9 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Jul 21, 2026, 10:10 PM EDT
Active, not recruiting No phase listed Observational

Automated Imaging Differentiation of Parkinsonism

NCT05913687
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
Interventions
AIDP
Diagnostic Test
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia

NCT00140413
View directory record Official record
Conditions
Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
Interventions
Nutropin AQ
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 5 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational

Does LMA Instead of ET Tube Affect Incidence of Postoperative Vomiting in Children Undergoing Strabismus Correction?

NCT00338559
View directory record Official record
Conditions
Strabismus
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 12 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 21, 2026, 10:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome

NCT00806182
View directory record Official record
Conditions
Opsoclonus-myoclonus Syndrome
Interventions
Not listed
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
1 Year to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

NCT03413319
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jul 21, 2026, 10:10 PM EDT